XBiotech
XBIT · Nasdaq · United States
Share price · XBIT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when XBIT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Oct 2026+7.6%
Nothing announced by XBIT that day or the session before.
- 26 Oct 2026-4.1%
- 19 Oct 2026-5.7%
- 12 Aug 2026+5.6%
- 6 Jul 2026+4.8%
Nothing announced by XBIT that day or the session before.
- 3 Dec 2025+11.6%
Nothing announced by XBIT that day or the session before.
- 1 Dec 2025+6.2%
Nothing announced by XBIT that day or the session before.
Share of unusual movement by asset
For each asset, the share of XBIT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 17% |
| Sessions with no dated event | — | 83% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(2 total)
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (19)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $4.7M | $105M | $4.5M-$4.5M operating cash flow | report ↗ |
View 18 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $5.3M | $110M | $6.7M-$4.5M operating cash flow | report ↗ |
| 2026-Q1 | $0 | — | $115M | —-$9.0M operating cash flow | report ↗ |
| 2025-Q3 | — | $5.1M | $147M | $6.0M-$4.3M operating cash flow | report ↗ |
| 2025-Q2 | — | $5.3M | $153M | $1.8M-$6.0M operating cash flow | report ↗ |
| 2025-Q1 | — | $12M | $156M | $11M-$6.7M operating cash flow | report ↗ |
| 2024-Q3 | — | $7.1M | $183M | $5.0M-$5.8M operating cash flow | report ↗ |
| 2024-Q2 | — | $13M | $189M | $13M-$11M operating cash flow | report ↗ |
| 2024-Q1 | — | $9.8M | $201M | $10M-$7.2M operating cash flow | report ↗ |
| 2023-Q4 | — | — | $200M+ $0 short-term inv. | $4.6M-$3.4M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $7.5M | $202M+ $0 short-term inv. | $7.4M-$1.5M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $11M | $143M+ $61M short-term inv. | $8.7M-$9.0M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $6.2M | $152M+ $60M short-term inv. | $3.8M-$4.8M operating cash flow | report ↗ |
| 2022-Q4 | — | — | $157M+ $60M short-term inv. | $3.2M$2.7M operating cash flow | report ↗ |
| 2022-Q3 | $1.7M | $7.0M | $161M+ $60M short-term inv. | $13M-$6.0M operating cash flow | report ↗ |
| 2022-Q2 | $1.5M | $10M | $226M | $12M-$6.4M operating cash flow | report ↗ |
| 2022-Q1 | $0.5M | $6.8M | $232M | $5.4M-$5.1M operating cash flow | report ↗ |
| 2021-Q4 | — | — | $237M+ $0 short-term inv. | $6.5M-$1.8M operating cash flow | report ↗ |
| 2021-Q3 | $4.5M | $5.6M | $239M | $3.3M-$3.4M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $47M | $126M | $11M-$40M operating cash flow | report ↗ |
For fiscal-year 2025, XBiotech did not disclose revenue. R&D spend was $47.39M, up 25.5% YoY from $37.76M. The company held $125.55M in cash and equivalents and reported a net loss of $45.54M, with quarterly net burn of $45.54M.
The company reported clinical progress across its True Human antibody pipeline. In oncology, Natrunix completed 120 weeks of dosing in a pancreatic cancer study, with reported reductions in hospitalization, serious adverse events and severe diarrhea, along with longer progression-free survival, and discussions with the FDA are ongoing. Its rheumatoid arthritis study was completed but deemed uninterpretable due to clinical-site irregularities, and that program was paused in December 2024. A Phase I stroke study of Hutrukin was completed, while a Phase II stroke study remains on hold. The infectious disease pipeline includes a clinical-stage MRSA therapeutic and preclinical programs for C. difficile, shingles and influenza, with investigational new drug applications for shingles and influenza targeted for the upcoming year.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $38M | $173M | $9.6M-$31M operating cash flow | report ↗ |
| 2023-FY | $0 | $33M | $200M+ $0 short-term inv. | $6.1M-$19M operating cash flow | report ↗ |
| 2022-FY | $4.0M | $32M | $157M+ $60M short-term inv. | $8.2M-$15M operating cash flow | report ↗ |
| 2021-FY | $18M | $28M | $237M+ $0 short-term inv. | $4.3M$69M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($855K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-03 | SIMARD JOHN · director, 10% owner | Open-market purchase | 70,000 | $2.05 | $143K | Form 4 |
| 2026-10-26 | SIMARD JOHN · director, 10% owner | Open-market purchase | 368,524 | $1.93 | $711K | Form 4 |
| 2026-10-26 | Simard Jan-Paul · Co-Chief Executive Officer | Award / grant (derivative) | 2,000,000 | — | — | Form 4 |
| 2025-10-01 | Troy Tevi David · director | Award / grant (derivative) | 56,000 | — | — | Form 4 |
| 2025-10-01 | Kuendig Thomas Martin · director | Award / grant (derivative) | 79,115 | — | — | Form 4 |
| 2025-10-01 | Soffer David Spencer · director | Award / grant (derivative) | 51,000 | — | — | Form 4 |
| 2025-10-01 | Rademaker Craig Evan · director | Award / grant (derivative) | 92,104 | — | — | Form 4 |
| 2025-03-17 | SIMARD JOHN · director, Chief Executive Officer, 10% owner | Award / grant (derivative) | 1,026,228 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 37 reporting institutions held 2.0M shares ($4.7M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 293,104 | $689K |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 231,020 | $543K |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 200,971 | $472K |
| 4 | RBF Capital, LLC | 198,501 | $466K |
| 5 | MORGAN STANLEY | 165,554 | $389K |
| 6 | MILLENNIUM MANAGEMENT LLC | 105,540 | $248K |
| 7 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 98,447 | $231K |
| 8 | VANGUARD FIDUCIARY TRUST CO | 91,576 | $215K |
| 9 | NORTHERN TRUST CORP | 76,087 | $179K |
| 10 | STATE STREET CORP | 73,006 | $172K |
| 11 | JANE STREET GROUP, LLC | 60,100 | $141K |
| 12 | Empowered Funds, LLC | 59,547 | $140K |
| 13 | Squarepoint Ops LLC | 41,214 | $97K |
| 14 | Bank of New York Mellon Corp | 39,355 | $92K |
| 15 | BANK OF AMERICA CORP /DE/ | 36,689 | $86K |